Assignee
EA PHARMA CO LTD
JP·17 granted patents·11 pending applications·39 citations·filing 2012–2024
Top patents by PatentIndex Score
28 records- 0185USRE49569EAlkylamine derivativeEA PHARMA CO LTD·Filed 2021·Granted Jul 4, 2023·1 cites·20 claims
- 0282US9533985B2Sulfonamide derivative and medicinal use thereofEA PHARMA CO LTD·Filed 2013·Granted Jan 3, 2017·15 cites·15 claims
- 0381US10562898B2Substituted benzenesulfonamides as inhibitors of alpha-4 beta-7 integrin activityEA PHARMA CO LTD·Filed 2017·Granted Feb 18, 2020·5 cites·20 claims
- 0481US9822110B2Sulfonamide derivative and pharmaceutical use thereofEA PHARMA CO LTD·Filed 2016·Granted Nov 21, 2017·6 cites·27 claims
- 0580US10626112B2Heterocyclic sulfonamide derivative and medicine comprising sameEA PHARMA CO LTD·Filed 2016·Granted Apr 21, 2020·2 cites·10 claims
- 0673US10166234B2Pharmaceutical preparation comprising phenylalanine derivativeEA PHARMA CO LTD·Filed 2018·Granted Jan 1, 2019·1 cites·13 claims
- 0773US9562043B2Heterocyclic amide derivative and pharmaceutical product containing sameEA PHARMA CO LTD·Filed 2014·Granted Feb 7, 2017·3 cites·11 claims
- 0870US9655879B2Heteroarylcarboxylic acid ester derivativeEA PHARMA CO LTD·Filed 2015·Granted May 23, 2017·1 cites·14 claims
- 0969US10183022B2Pharmaceutical composition for treating ulcerative colitisEA PHARMA CO LTD·Filed 2017·Granted Jan 22, 2019·2 cites·11 claims
- 1068US10039763B2Pharmaceutical preparation comprising phenylalanine derivativeEA PHARMA CO LTD·Filed 2012·Granted Aug 7, 2018·1 cites·17 claims
- 1166US11311508B2Medicinal composition for preventing or treating secondary hyperparathyroidism under maintenance dialysisEA PHARMA CO LTD·Filed 2018·Granted Apr 26, 2022·1 cites·15 claims
- 1257US2024262805A1Method for producing compound or pharmaceutically acceptable salt thereofEA PHARMA CO LTD·Filed 2024·Application pending·0 cites
- 1356US10226400B2Multi-cell containerEA PHARMA CO LTD·Filed 2013·Granted Mar 12, 2019·1 cites·10 claims
- 1456US9440980B2Remedy for diabetesEA PHARMA CO LTD·Filed 2014·Granted Sep 13, 2016·0 cites·18 claims
- 1556US2021206773A1Drug for treating disorders of corneal epitheliumEA PHARMA CO LTD·Filed 2021·Application pending·0 cites
- 1655US12023320B2Therapeutic agent for fatty liver diseaseEA PHARMA CO LTD·Filed 2023·Granted Jul 2, 2024·0 cites·11 claims
- 1749US2018230122A1Production method for heteroarylcarboxylic acid ester derivative, production intermediate thereof, and crystalEA PHARMA CO LTD·Filed 2018·Application pending·0 cites
- 1845US10584116B2Heterocyclic sulfonamide derivative and medicine containing sameEA PHARMA CO LTD·Filed 2018·Granted Mar 10, 2020·0 cites·19 claims
- 1945US2017369494A1Drug for treating disorders of corneal epitheliumEA PHARMA CO LTD·Filed 2015·Application pending·0 cites
- 2045US2016376249A1Production method for heteroarylcarboxylic acid ester derivative, production intermediate thereof, and crystalEA PHARMA CO LTD·Filed 2016·Application pending·0 cites
- 2144US2022142958A1Medicinal composition having excellent stabilityEA PHARMA CO LTD·Filed 2020·Application pending·0 cites
- 2242US2018162844A1Cyclopropane derivative and drug containing sameEA PHARMA CO LTD·Filed 2018·Application pending·0 cites
- 2341US2017151200A1Prophylactic or therapeutic agent for idiopathic inflammatory myopathiesEA PHARMA CO LTD·Filed 2017·Application pending·0 cites
- 2437US2020229955A1Stent and medical device comprising sameEA PHARMA CO LTD·Filed 2020·Application pending·0 cites
- 2533US9883986B2Standing bag type infusion liquid containerEA PHARMA CO LTD·Filed 2014·Granted Feb 6, 2018·0 cites·9 claims
- 2633US2017143738A1Solid formulation and method for stabilizing the sameEA PHARMA CO LTD·Filed 2015·Application pending·0 cites
- 2731US10420741B2Megalin antagonistEA PHARMA CO LTD·Filed 2016·Granted Sep 24, 2019·0 cites·11 claims
- 2826US2016376248A1Method for producing heteroarylcarboxylic acid ester derivative, and production intermediate of sameEA PHARMA CO LTD·Filed 2016·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →